Merck's Zostavax is the only shingles vaccine approved in the U.S. and EU, but it may not be for long. Based on results from two Phase III trials involving more than 16,000 older adults, GlaxoSmithKline plans to submit a regulatory filing for its shingles candidate, dubbed Shingrix, in North America, Japan and the EU in the second half of 2016.
The CDC doesn't currently recommend Merck's shingles vaccine, Zostavax, for those between the ages of 50 and 60. And a new analysis of the vaccine's cost-effectiveness in that population suggests it should stay that way.
A Kaiser Permanente study shows that the shingles vaccine can reduce the long-term pain of those who contracted the disease even though they were vaccinated.
Zostavax is the only shingles vaccine approved in the U.S. and the EU, but GlaxoSmithKline is one step closer to changing that. On Tuesday, the British pharma announced Phase III results for its shingles candidate, HZ/su, reporting an overall efficacy of 97.2% compared with placebo.
GlaxoSmithKline's in-development shingles vaccine successfully staved off the virus in a massive Phase III study--and, in contrast with its top competitor, the shot's effects didn't wane among elderly patients.
While GlaxoSmithKline is still awaiting late-stage results for its shingles vaccine, HZ/su, Cowen & Co. analysts believe the vaccine may just be better than Merck's Zostavax.
More than four years ago, GlaxoSmithKline began a Phase III study of a shingles candidate it hoped would eventually mount a challenge to Merck's Zostavax. Now, that candidate is one step closer after hitting its primary endpoint in that trial.
Not enough people are being vaccinated against shingles, and those who are at the highest risk for the painful viral infection, such as those with immunosuppressive disorders like HIV, are not able to receive the vaccine because of safety issues, according to a new study.
The National Adult Vaccination Program and others have proposed strategies to raise the proportion of adults getting vaccinated against pneumococcal disease, shingles and hepatitis B, but the latest data shows little change in immunization rates.
Quidel has its latest molecular diagnostic test approval in hand, this time a CE mark for a blood test that screens for herpes plus a virus that causes chicken pox and shingles.